fine line chemotherapy
Showing 1 - 25 of >10,000
Advanced Colorectal Cancer Trial in Hangzhou (Fruquintinib Combined With Chemotherapy)
Not yet recruiting
- Advanced Colorectal Cancer
- Fruquintinib Combined With Chemotherapy
-
Hangzhou, Zhejing, ChinaZhejiang Cancer Institute & Hospital
Jun 29, 2023
Tislelizumab Combined With Chemotherapy in First-line Treatment
Active, not recruiting
- Tislelizumab
- +3 more
-
Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 6, 2023
Gastrointestinal Neuroendocrine Carcinoma Trial in Beijing (Durvalumab and Chemotherapy(oxaliplatin and capecitabine))
Recruiting
- Gastrointestinal Neuroendocrine Carcinoma
- Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 1, 2023
Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)
Not yet recruiting
- Advanced Mucosal Melanoma
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- (no location specified)
Sep 15, 2023
ASCT Versus Chemotherapy as First-Line Consolidation Therapy
Completed
- T-cell Lymphoma Adults
- consolidation with ASCT
- (no location specified)
Nov 25, 2023
Cancer Of Pancreas Trial (Analyze of GemCore status)
Not yet recruiting
- Cancer Of Pancreas
- Analyze of GemCore status
- (no location specified)
Sep 19, 2023
Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)
Recruiting
- Biliary Tract Neoplasms
- Immunotherapy
- Durvalumab
- +2 more
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Jul 6, 2023
NSCLC Trial (Ivonescimab Injection, Pembrolizumab Injection)
Not yet recruiting
- Non-Small Cell Lung Cancer
- Ivonescimab Injection
- Pembrolizumab Injection
- (no location specified)
Jun 9, 2023
HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)
Recruiting
- HR Positive HER2 Negative Advanced Breast Cancer
-
Tianjin, China天津市肿瘤医院
May 26, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)
Not yet recruiting
- Nasopharyngeal Carcinoma
- BL-B01D1
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Oct 31, 2023
Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)
Not yet recruiting
- Breast Cancer
- Dalpiciclib combined with Letrozole
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Aug 3, 2023
High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation Trial in Shanghai
Recruiting
- High-risk Stage II Colorectal Cancer
- +2 more
- mFOLFIRINOX adjuvant chemotherapy
- mFOLFOX6/XELOX adjuvant chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 12, 2023
First-Line Serplulimab Plus Chemotherapy in Treatment of
Not yet recruiting
- Lung Cancer
- Serplulimab plus chemotherapy
- (no location specified)
May 16, 2023
Hepatocellular Carcinoma Trial in Hangzhou (PM8002, FOLFOX regimen)
Recruiting
- Hepatocellular Carcinoma
- PM8002
- FOLFOX regimen
-
Hangzhou, Zhejiang, ChinaCancer Hospital of The University of Chinese Academy of Sciences
May 19, 2023
Pleural Mesothelioma Trial in Guangzhou (Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin)
Not yet recruiting
- Pleural Mesothelioma
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jul 3, 2023
Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC
Completed
- Non-small Cell Lung Cancer
- Lazertinib
- Platinum-based Chemotherapy
- (no location specified)
May 8, 2023
Metastatic Pancreatic Cancer Trial (FOLFIRINOX treatment)
Not yet recruiting
- Metastatic Pancreatic Cancer
- FOLFIRINOX treatment
- (no location specified)
Aug 9, 2023
NSCLC Stage II, Bevacizumab, Immunotherapy Trial in Guangzhou (Serplulimab combined with bevacizumab and first-line chemo)
Not yet recruiting
- Non-small Cell Lung Cancer Stage II
- +3 more
- Serplulimab combined with bevacizumab and first-line chemotherapy
-
Guangzhou, Guangdong, ChinaLikun Chen
Apr 10, 2023
Pancreatic Cancer, Ultrasonography, First-line Chemo Trial in Beijing (Contrast-enhanced ultrasound(CEUS))
Recruiting
- Pancreatic Cancer
- +2 more
- Contrast-enhanced ultrasound(CEUS)
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Feb 6, 2023
Solid Tumor Trial in Beijing (QLS31905, Nab paclitaxel, Gemcitabine)
Not yet recruiting
- Solid Tumor
- QLS31905
- +5 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Sep 10, 2023
Hepatocellular Carcinoma Trial in Nanjing, Shanghai (QL1706, Bevacizumab, Oxaliplatin injection)
Not yet recruiting
- Hepatocellular Carcinoma
- QL1706
- +4 more
-
Nanjing, Jiangsu, China
- +1 more
Jul 28, 2023
Gynecologic Cancer Trial (Experimental product - Fortifit® Powder, Standard of care)
Not yet recruiting
- Gynecologic Cancer
- Experimental product - Fortifit® Powder
- Standard of care
- (no location specified)
Oct 14, 2023